These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Restenosis related to percutaneous coronary intervention has been solved? Kivelä A; Hartikainen J Ann Med; 2006; 38(3):173-87. PubMed ID: 16720432 [TBL] [Abstract][Full Text] [Related]
6. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease. Kohn J; Zeltinger J Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093 [TBL] [Abstract][Full Text] [Related]
7. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Beijk MA; Piek JJ Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467 [TBL] [Abstract][Full Text] [Related]
8. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023 [TBL] [Abstract][Full Text] [Related]
10. Drug-eluting stents: a pharmacoclinical perspective. Thomas MK; Gupta YK Natl Med J India; 2006; 19(4):195-9. PubMed ID: 17100106 [TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale. Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384 [TBL] [Abstract][Full Text] [Related]
13. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841 [TBL] [Abstract][Full Text] [Related]
14. Drug-eluting coronary stents: many meta-analyses, little benefit. Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727 [TBL] [Abstract][Full Text] [Related]
15. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results. Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205 [TBL] [Abstract][Full Text] [Related]
16. Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives. Birkenhauer P; Yang Z; Gander B J Pharm Pharmacol; 2004 Nov; 56(11):1339-56. PubMed ID: 15525440 [TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626 [TBL] [Abstract][Full Text] [Related]
18. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. Kelbaek H; Helqvist S; Thuesen L; Kløvgaard L; Jørgensen E; Saunamäki K; Krusell LR; Bøtker HE; Engstrøm T; Jensen GV; Am Heart J; 2006 Nov; 152(5):882-6. PubMed ID: 17070149 [TBL] [Abstract][Full Text] [Related]
19. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents. Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063 [TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL; Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]